Cyproheptadine


First-generation antihistamine + 5-HT2 antagonist

A piperidine first-generation antihistamine with 5-HT2A and 5-HT2C antagonist activity; used for appetite stimulation, serotonin syndrome reversal, and migraine prophylaxis.

Abstract

Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; CAS 129-03-3; molecular formula C21H21N; molecular weight 287.40) is a piperidine first-generation antihistamine with potent 5-HT2A and 5-HT2C antagonist activity, approved by the FDA in 1961 (Periactin). The compound combines H1 antihistamine activity (Ki approximately 1 nM, comparable to diphenhydramine) with strong 5-HT2 antagonism (Ki approximately 1 nM at 5-HT2A); the combined activity drives appetite stimulation (5-HT2C antagonism, the same mechanism as the appetite gain seen with olanzapine and clozapine), serotonin syndrome reversal, and migraine prophylaxis. Plasma half-life is approximately 8 hours. Approved for allergic conditions; off-label use in failure-to-thrive (pediatric appetite stimulation), serotonin syndrome (the only specific antidote besides supportive care), and post-SSRI sexual dysfunction (5-HT2A antagonism). Used as the canonical 5-HT2 antagonist antihistamine in research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph